Amgen's Blincyto (blinatumomab) Receives EU Expanded Indication Approval for Ph- CD19 Positive B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Shots:
- The expanded approval is based on P-II BLAST study results assessing Blincyto (15ug/m2/d @4wks.) in patients with 3L + MRD-positive ALL in complete hematologic remission- evaluating its efficacy- safety- and tolerability
- The study resulted in complete MRD response or no detectable MRD- relapse-free survival- eliminating detectable residual disease with safe and effective results in the study
- Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T cell engager (BiTE) immunotherapy and has received the US FDA approval for B-cell precursor ALL in first or second complete remission with MRD greater than or equal to 0.1 percent in adults and children
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
